Nonalcoholic Fatty Liver Disease (NAFLD) Database 3

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1649 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-11-13

Study Completion Date

2025-07-09

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The NAFLD Database 3 will enroll approximately 1500 adult patients and 750 pediatric patients suspected or known to have NAFLD or NASH-related cirrhosis. To elucidate, through the cooperative effort of a multidisciplinary and multicenter group of collaborators, the etiology, natural history, diagnosis, treatment, and prevention of NAFLD, and in particular its more severe form of NASH and its complications.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

European Paediatric Non-Alcoholic Fatty Liver Disease Registry (EU-PNAFLD)

NCT04190849

Non-Alcoholic Fatty Liver Disease Non-alcoholic Fatty Liver Non-alcoholic Steatohepatitis

RECRUITING

A Single-Ascending and Repeated Dose Study of LY3849891 in Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

NCT05395481

Metabolic Dysfunction-Associated Steatohepatitis (MASH) Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)

ACTIVE_NOT_RECRUITING PHASE1

Non-Invasive Diagnostic Tests for MASLD in Pediatric Population

NCT06218589

Metabolic Dysfunction Associated Steatotic Liver Disease Non-Alcoholic Fatty Liver Disease (NAFLD)

RECRUITING NA

Assessment of Non-Invasive Testing in Major Liver-Related Outcomes

NCT06986447

Metabolic Dysfunction-Associated Steatotic Liver Disease MASLD MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease +2 more

NOT_YET_RECRUITING

Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD Study

NCT04550481

Hepatocellular Carcinoma Nonalcoholic Steatohepatitis

ACTIVE_NOT_RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a multicenter, prospective follow-up study of patients with known nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH). The primary objective of the study is to investigate the etiology, pathogenesis, natural history, diagnosis, treatment, and prevention of NAFLD and NASH.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Liver Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Adult patients with NAFLD

1500 patients 18 years and older at the time of enrollment.

No interventions assigned to this group

Pediatric patients with NAFLD

750 patients 2 years or older and up to 17 years old at the time of enrollment.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 2 years of age or older as of the initial screening interview and provision of consent
* Willingness to participate in the study for 1 or more years
* Histologic evidence of NAFLD or NASH based upon a standard of care liver biopsy
* Collection of serum and plasma up to 90 days before or 4- 90 days after standard of care liver biopsy
* Absence of regular or excessive use of alcohol within 2 years prior to initial screening

Exclusion Criteria

* Clinical or histological evidence of alcoholic liver disease: Regular and excessive use of alcohol within the 2 years prior to interview defined as alcohol intake greater than 14 drinks per week in a man or greater than 7 drinks per week in a woman. Approximately 10 g of alcohol equals one 'drink' unit. One unit equals 1 ounce of distilled spirits, one 12-oz beer, or one 4-oz glass of wine
* Total parenteral nutrition for more than 1 month within a 6-month period before baseline liver biopsy
* Short bowel syndrome
* History of gastric or jejunoileal bypass preceding the diagnosis of NAFLD. Bariatric surgery performed following enrollment is not exclusionary. Liver biopsies obtained during bariatric surgery cannot be used for enrollment because of the associated surgical or anesthetic acute changes and the weight loss efforts that precede bariatric surgery
* History of biliopancreatic diversion
* Evidence of advanced liver disease defined as a Child-Pugh-Turcotte score equal to or greater than 10
* Evidence of chronic hepatitis B as marked by the presence of HBsAg in serum (patients with isolated antibody to hepatitis B core antigen, anti-HBc total, are not excluded)
* Evidence of chronic hepatitis C as marked by the presence of anti-HCV or HCV RNA in serum
* Low alpha-1-antitrypsin level and ZZ phenotype (both determined at the discretion of the investigator)
* Wilson's disease
* Known glycogen storage disease
* Known dysbetalipoproteinemia
* Known phenotypic hemochromatosis (HII greater than 1.9 or removal of more than 4 g of iron by phlebotomy)
* Prominent bile duct injury (florid duct lesions or periductal sclerosis) or bile duct paucity
* Chronic cholestasis
* Vascular lesions (vasculitis, cardiac sclerosis, acute or chronic Budd-Chiari, hepatoportal sclerosis, peliosis)
* Iron overload greater than 3+
* Zones of confluent necrosis, infarction, massive or sub-massive, pan-acinar necrosis
* Multiple epithelioid granulomas
* Congenital hepatic fibrosis
* Polycystic liver disease
* Other metabolic or congenital liver disease
* Evidence of systemic infectious disease
* Known HIV positive
* Disseminated or advanced malignancy
* Concomitant severe underlying systemic illness that in the opinion of the investigator would interfere with completion of follow-up
* Active drug use or dependence that, in the opinion of the study investigator, would interfere with adherence to study requirements
* Any other condition, which in the opinion of the investigator would impede compliance or hinder completion of study
* Inability to complete the appropriate informed consent process

Minimum Eligible Age

2 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No